CN109125411A - 治疗骨质疏松的全鹿胶及其制备方法 - Google Patents
治疗骨质疏松的全鹿胶及其制备方法 Download PDFInfo
- Publication number
- CN109125411A CN109125411A CN201811230860.9A CN201811230860A CN109125411A CN 109125411 A CN109125411 A CN 109125411A CN 201811230860 A CN201811230860 A CN 201811230860A CN 109125411 A CN109125411 A CN 109125411A
- Authority
- CN
- China
- Prior art keywords
- deer
- full
- horn glue
- treatment
- horn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
本发明提供治疗骨质疏松的全鹿胶及其制备方法,按质量计,包括如下组份:鹿角100‑500克,鹿茸300‑600g,鹿皮400‑600g,鹿筋100‑500g,鹿骨100‑500g,鹿尾200‑600g,鹿血40‑110g,鹿鞭50‑70g,鹿心20‑80g,鹿腰30‑60g,鹿肝40‑90g,鹿肺40‑50g,鹿肠20‑50g,党参5‑15g,肉苁蓉5‑15g,灵芝6‑10g,黄芪5‑10g;制备方法:备原料;将原料放入水中,从水沸腾开始计时,煎煮4‑6h,然后过滤固体物及滤渣,得浸提液一;把所述固体物及滤渣再次放入水中,从水沸腾开始计时,煎煮2‑3h,然后过滤得浸提液二;将浸提液二依次经过滤,冷却和浓缩,得到成品全鹿胶;本发明提供治疗骨质疏松的全鹿胶,解决现有西药治疗骨质疏松,用药贵,并易产生并发症的缺陷。
Description
技术领域
本发明涉及中药组合物技术领域,具体涉及治疗骨质疏松的全鹿胶及其制备方法。
背景技术
骨质疏松是一种常见的,全身性的骨代谢疾病,其特征在是骨量减少、骨组织微结构退化,导致骨脆性增加从而引起的腰背疼痛、骨密度下降、骨折等常见症状,并会发生身长缩短及驼背等,骨质疏松导致代谢紊乱,从而造成血钙偏高,由此引起一系列的与钙代谢紊乱相关的并发症,如高血压,冠心病及动脉硬化等,骨质疏松引起的各种疾病严重影响了中老年尤其是绝经后妇女的生活质量,加上医疗费用支出增多,寿命的缩短等不仅对患者的身心健康造成危害,也增加了家庭和社会的经济负担,已被公认为仅次于心血管疾病的第二大健康杀手,因此骨质疏松的防治是当前极为迫切的一项重大难题。
目前防治骨质疏松的西药药物主要有基础性用药(例如维生素D)、骨吸收抑制剂(例如降钙素),虽然治疗效果显著,但其昂贵的价格及可能引起的一系列并发症,导致患者苦不堪言。
发明内容
为了克服现有技术缺陷,本发明提供治疗骨质疏松的全鹿胶,解决现有西药治疗骨质疏松,用药贵,并易产生并发症的缺陷。
治疗骨质疏松的全鹿胶,按质量计,包括如下组份:鹿角100-500克,鹿茸300-600g,鹿皮400-600g,鹿筋100-500g,鹿骨100-500g,鹿尾200-600g,鹿血40-110g,鹿鞭50-70g,鹿心20-80g,鹿腰30-60g,鹿肝40-90g,鹿肺40-50g,鹿肠20-50g,党参5-15g,肉苁蓉5-15g,灵芝6-10g,黄芪5-10g。
优选的,按质量计,包括如下组份:鹿角300-500克,鹿茸400-600g,鹿皮500-600g,鹿筋200-500g,鹿骨400-500g,鹿尾300-600g,鹿血40-80g,鹿鞭50-60g,鹿心20-50g,鹿腰30-50g,鹿肝40-50g,鹿肺45-50g,鹿肠40-50g,党参10-15g,肉苁蓉10-15g,灵芝8-10g,黄芪7-10g。
优选的,按质量计,包括如下组份:鹿角500g,鹿茸500g,鹿皮500g,鹿角500g,鹿筋500g,鹿骨500g,鹿尾500g,鹿血50g,鹿鞭50g,鹿心50g,鹿腰50g,鹿肝50g,鹿肺50g,鹿肠50g,党参10g,肉苁蓉10g,灵芝10g,黄芪10g。
优选的,全鹿胶还包括甜度调节剂10-20克,甜度调节剂采用木糖醇或甜菊糖。
进一步的,全鹿胶还包括复合稳定剂10-15克,复合稳定剂由EDTA和柠檬酸汁构成,EDTA和柠檬酸汁的质量比为1-3:1。
进一步的,全鹿胶还包括复合分散剂5-10克,复合分散剂包括明胶和失水山梨醇单硬脂酸酯,明胶和失水山梨醇单硬脂酸酯的质量比为2-5:1。
针对上述治疗骨质疏松的全鹿胶,提供与其对应的制备方法,具体包括如下步骤:
(1)按上述组份准备原料,清洗干净;
(2)将鹿角、鹿茸、鹿皮、鹿筋、鹿骨、鹿尾、鹿血、鹿鞭、鹿心、鹿腰、鹿肝、鹿肺、鹿肠、党参、肉苁蓉、灵芝及黄芪放入水中,从水沸腾开始计时,煎煮4-6h,优选5h,然后过滤固体物及滤渣,得浸提液一,其中水的用量是鹿角、鹿茸、鹿皮、鹿筋、鹿骨、鹿尾、鹿血、鹿鞭、鹿心、鹿腰、鹿肝、鹿肺、鹿肠、党参、肉苁蓉、灵芝及黄芪总重的1.3-1.4倍,优选1.3倍;
(3)把所述固体物及滤渣再次放入水中,从水沸腾开始计时,煎煮2-3h,优选2.5h,然后过滤得浸提液二,其中水的用量是固体物及滤渣总重的1.1-1.2倍,优选1.1倍;
(4)将浸提液二依次经过滤,冷却和浓缩,得到成品全鹿胶。
进一步的,所述步骤(3)中,在将浸提液二过滤之前,添加甜味调节剂10-20克,搅拌均匀。
进一步的,所述步骤(3)中,在将浸提液二过滤之前,添加复合稳定剂10-15克,复合稳定剂由EDTA和柠檬酸汁构成,EDTA和柠檬酸汁的质量比为1-3:1。
进一步的,在添加复合稳定剂的同时,添加复合分散剂5-10克,复合分散剂包括明胶和失水山梨醇单硬脂酸酯,明胶和失水山梨醇单硬脂酸酯的质量比为2-5:1。
和最接近的现有技术比,本发明的技术方案具备如下有益效果:
本发明的全鹿胶,从中药角度,以补肾壮骨为理论指导,具有温肾壮阳,温通经脉,气血交补,填补精髓,补肾健脾的作用,从而达到治疗骨质疏松的目的,并且,相对于西药治疗骨质疏松,便宜实用,发生并发症的概率低。
本发明的全鹿胶,作为优选,添加甜味调节剂。改善全鹿胶的口感,便于患者服用,并且优先选用木糖醇或甜菊糖作为甜味调节剂,不会产生大量热量。
本发明的全鹿胶,作为优选,添加由EDTA和柠檬酸汁构成的复合稳定剂,一方面,延长了全鹿胶的保质期,另一方面,锁定全鹿胶的水分,使得暴露在空气的较长时间内全鹿胶不会变硬。
本发明的全鹿胶,作为优选,添加明胶和失水山梨醇单硬脂酸酯构成的复合分散剂,加快复合稳定剂在浸提液的分散溶解,提高复合稳定剂在浸提液的溶解度。
具体实施方式
下面将结合具体实施例,对本发明的技术方案进行清楚、完整地描述。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
治疗骨质疏松的全鹿胶,按质量计,包括如下组份:鹿角100克,鹿茸300g,鹿皮400g,鹿筋100-g,鹿骨100g,鹿尾200g,鹿血40g,鹿鞭50g,鹿心20g,鹿腰30g,鹿肝40g,鹿肺40g,鹿肠20g,党参5g,肉苁蓉5g,灵芝6g,黄芪5g。
针对上述治疗骨质疏松的全鹿胶,提供与其对应的制备方法,具体包括如下步骤:
(1)按上述组份准备原料,清洗干净;
(2)将鹿角、鹿茸、鹿皮、鹿筋、鹿骨、鹿尾、鹿血、鹿鞭、鹿心、鹿腰、鹿肝、鹿肺、鹿肠、党参、肉苁蓉、灵芝及黄芪放入水中,从水沸腾开始计时,煎煮4-6h,然后过滤固体物及滤渣,得浸提液一,其中水的用量是鹿角、鹿茸、鹿皮、鹿筋、鹿骨、鹿尾、鹿血、鹿鞭、鹿心、鹿腰、鹿肝、鹿肺、鹿肠、党参、肉苁蓉、灵芝及黄芪总重的1.3-1.4倍;
(3)把所述固体物及滤渣再次放入水中,从水沸腾开始计时,煎煮2-3h,然后过滤得浸提液二,其中水的用量是固体物及滤渣总重的1.1-1.2倍;
(4)将浸提液二依次经过滤,冷却和浓缩,得到成品全鹿胶。
实施例2
治疗骨质疏松的全鹿胶,按质量计,包括如下组份:鹿角500克,鹿茸600g,鹿皮600g,鹿筋500g,鹿骨500g,鹿尾600g,鹿血110g,鹿鞭70g,鹿心80g,鹿腰60g,鹿肝90g,鹿肺50g,鹿肠50g,党参15g,肉苁蓉15g,灵芝10g,黄芪10g。
本实施例的全鹿胶的制备方法同实施例1。
实施例3
治疗骨质疏松的全鹿胶,按质量计,包括如下组份:鹿角300克,鹿茸400g,鹿皮50g,鹿筋200g,鹿骨400g,鹿尾300g,鹿血80g,鹿鞭60g,鹿心50g,鹿腰50g,鹿肝50g,鹿肺45g,鹿肠40g,党参15g,肉苁蓉15g,灵芝8g,黄芪7g。
本实施例的全鹿胶的制备方法同实施例1。
实施例4
治疗骨质疏松的全鹿胶,按质量计,包括如下组份:鹿角500g,鹿茸500g,鹿皮500g,鹿角500g,鹿筋500g,鹿骨500g,鹿尾500g,鹿血50g,鹿鞭50g,鹿心50g,鹿腰50g,鹿肝50g,鹿肺50g,鹿肠50g,党参10g,肉苁蓉10g,灵芝10g,黄芪10g。
本实施例的全鹿胶的制备方法同实施例1。
实施例5
本实施例在实施例1的基础上,全鹿胶的原料进一步包括甜度调节剂10-20克,甜度调节剂采用木糖醇或甜菊糖,产生热量低,益于人体健康。
本实施例的全鹿胶的制备方法基本同实施例1相同,不同之处在于,步骤(4)中,将浸提液二过滤前,添加甜度调节剂,搅拌均匀。
实施例6
本实施例在实施例1的基础上,全鹿胶的原料进一步包括复合稳定剂10-15克,复合稳定剂由EDTA和柠檬酸汁构成,EDTA和柠檬酸汁的质量比为1-3:1,优选的,EDTA和柠檬酸汁的质量比为2:1,复合稳定剂的添加,一方面,延长了全鹿胶的保质期,另一方面,锁定全鹿胶的水分,使得暴露在空气的较长时间内全鹿胶不会变硬。
本实施例的全鹿胶的制备方法,在实施例1的基础上,步骤(3)中,在将浸提液二过滤之前,添加上述复合稳定剂。
实施例7
本实施例在实施例6的基础上,全鹿胶的原料进一步包括复合分散剂5-10克,加快复合稳定剂在浸提液的分散溶解,提高复合稳定剂在浸提液的溶解度;复合分散剂包括明胶和失水山梨醇单硬脂酸酯,明胶和失水山梨醇单硬脂酸酯的质量比为2-5:1,优选的,明胶和失水山梨醇单硬脂酸酯的质量比为2:1。
本实施例的全鹿胶的制备方法,在实施例6的基础上,步骤(3)中,在将浸提液二过滤之前,添加复合稳定剂的同时,添加上述复合分散剂。
下面对本发明实施例1的全鹿胶,针对其治疗骨质疏松做如下性能试验:
破骨细胞骨吸收功能抑制是治疗骨质疏松症的主要途径,吸收陷窝计数是用于评价药物对破骨细胞抑制作用的药效指标,吸收陷窝计数越小,说明药物对破骨细胞抑制作用越明显,因此下面通过试验测定吸收陷窝数,以此验证本发明全鹿胶具有治疗骨质增生的功效;
(1)随机选取20只大鼠,背侧切开妇腔,做双侧卵巢切除;
(2)三个月后,小鼠无死亡,随机选取10只作为对照组,对照组灌胃生理盐水,每天一次,每次每只小鼠灌胃10毫克,连续10周重复操作;另外10只作为试验组,试验组灌胃本发明实施例1的全鹿胶稀释液(即把全鹿胶加热融化,加水稀释,然后冷却制得,其中稀释过程中,用水量是全鹿胶重量的3倍,稀释不影响全鹿胶的功效),每天一次,每次每只小鼠灌胃10毫克,连续10周重复操作;
(3)分别将对照组和试验组的大鼠消毒,在无菌条件下取大鼠的四肢长骨,机械分离破骨细胞,以5×104/cm2的密度接种于牛皮质骨薄切片上(5mm×5mm),培养液为体积分数15%FCS-MEN,置于37摄氏度、体积分数5%CO2培养箱内培养;
(4)细胞培养3天取出骨片超声去除细胞后,经体积分数1%甲苯胺蓝染色,光学显微镜下分别对对照组和试验组的大鼠骨片作吸收陷窝计数;
(5)通过吸收陷窝计数得出平均吸收陷窝计数:对照组的平均吸收陷窝计数=10只对照组大鼠骨片吸收陷窝计数累计加和/10;试验组的平均吸收陷窝计数=10只试验组大鼠骨片吸收陷窝计数累计加和/10;
结果如下表1:
表1
组别 | 平均吸收陷窝计数 |
对照组 | 132 |
试验组 | 38 |
通过表1可以看出:试验组的平均吸收陷窝计数,远远低于对照组的平均吸收陷窝计数,可见本发明实施例1的全鹿胶对破骨细胞具有很好的抑制作用,从而本发明的全鹿胶对骨质疏松症的治疗效果明显。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (10)
1.治疗骨质疏松的全鹿胶,其特征在于,按质量计,包括如下组份:鹿角100-500克,鹿茸300-600g,鹿皮400-600g,鹿筋100-500g,鹿骨100-500g,鹿尾200-600g,鹿血40-110g,鹿鞭50-70g,鹿心20-80g,鹿腰30-60g,鹿肝40-90g,鹿肺40-50g,鹿肠20-50g,党参5-15g,肉苁蓉5-15g,灵芝6-10g,黄芪5-10g。
2.根据权利要求1所述的治疗骨质疏松的全鹿胶,其特征在于,按质量计,包括如下组份:鹿角300-500克,鹿茸400-600g,鹿皮500-600g,鹿筋200-500g,鹿骨400-500g,鹿尾300-600g,鹿血40-80g,鹿鞭50-60g,鹿心20-50g,鹿腰30-50g,鹿肝40-50g,鹿肺45-50g,鹿肠40-50g,党参10-15g,肉苁蓉10-15g,灵芝8-10g,黄芪7-10g。
3.根据权利要求1所述的治疗骨质疏松的全鹿胶,其特征在于,按质量计,包括如下组份:鹿角500g,鹿茸500g,鹿皮500g,鹿角500g,鹿筋500g,鹿骨500g,鹿尾500g,鹿血50g,鹿鞭50g,鹿心50g,鹿腰50g,鹿肝50g,鹿肺50g,鹿肠50g,党参10g,肉苁蓉10g,灵芝10g,黄芪10g。
4.根据权利要求1所述的治疗骨质疏松的全鹿胶,其特征在于,还包括甜度调节剂10-20克,甜度调节剂采用木糖醇或甜菊糖。
5.根据权利要求1所述的治疗骨质疏松的全鹿胶,其特征在于,还包括复合稳定剂10-15克,复合稳定剂由EDTA和柠檬酸汁构成,EDTA和柠檬酸汁的质量比为1-3:1。
6.根据权利要求5所述的治疗骨质疏松的全鹿胶,其特征在于,还包括复合分散剂5-10克,复合分散剂包括明胶和失水山梨醇单硬脂酸酯,明胶和失水山梨醇单硬脂酸酯的质量比为2-5:1。
7.根据权利要求1所述的治疗骨质疏松的全鹿胶的制备方法,其特征在于,包括如下步骤:
(1)按上述组份准备原料,清洗干净;
(2)将鹿角、鹿茸、鹿皮、鹿筋、鹿骨、鹿尾、鹿血、鹿鞭、鹿心、鹿腰、鹿肝、鹿肺、鹿肠、党参、肉苁蓉、灵芝及黄芪放入水中,从水沸腾开始计时,煎煮4-6h,然后过滤固体物及滤渣,得浸提液一,其中水的用量是鹿角、鹿茸、鹿皮、鹿筋、鹿骨、鹿尾、鹿血、鹿鞭、鹿心、鹿腰、鹿肝、鹿肺、鹿肠、党参、肉苁蓉、灵芝及黄芪总重的1.3-1.4倍;
(3)把所述固体物及滤渣再次放入水中,从水沸腾开始计时,煎煮2-3h,然后过滤得浸提液二,其中水的用量是固体物及滤渣总重的1.1-1.2倍;
(4)将浸提液二依次经过滤,冷却和浓缩,得到成品全鹿胶。
8.根据权利要求7所述的治疗骨质疏松的全鹿胶的制备方法,其特征在于,所述步骤(3)中,在将浸提液二过滤之前,添加甜味调节剂10-20克,搅拌均匀。
9.根据权利要求7所述的治疗骨质疏松的全鹿胶的制备方法,其特征在于,所述步骤(3)中,在将浸提液二过滤之前,添加复合稳定剂10-15克,复合稳定剂由EDTA和柠檬酸汁构成,EDTA和柠檬酸汁的质量比为1-3:1。
10.根据权利要求9所述的治疗骨质疏松的全鹿胶的制备方法,其特征在于,在添加复合稳定剂的同时,添加复合分散剂5-10克,复合分散剂包括明胶和失水山梨醇单硬脂酸酯,明胶和失水山梨醇单硬脂酸酯的质量比为2-5:1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811230860.9A CN109125411A (zh) | 2018-10-22 | 2018-10-22 | 治疗骨质疏松的全鹿胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811230860.9A CN109125411A (zh) | 2018-10-22 | 2018-10-22 | 治疗骨质疏松的全鹿胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109125411A true CN109125411A (zh) | 2019-01-04 |
Family
ID=64809244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811230860.9A Pending CN109125411A (zh) | 2018-10-22 | 2018-10-22 | 治疗骨质疏松的全鹿胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109125411A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108815193A (zh) * | 2018-08-22 | 2018-11-16 | 宋子刚 | 一项仙鹿膏的中药配方及制备方法 |
CN113142565A (zh) * | 2021-04-19 | 2021-07-23 | 侯君才 | 一种鹿胶及其制备方法 |
CN114306387A (zh) * | 2022-01-19 | 2022-04-12 | 贵州广济堂健康药业有限公司 | 促进骨形成的药物及促进骨形成的方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1197841A (zh) * | 1998-05-26 | 1998-11-04 | 倪颖 | 鹿宝酒及制备方法 |
CN104997079A (zh) * | 2015-08-06 | 2015-10-28 | 万雄集团股份有限公司 | 一种全鹿中药保健汤及其制备方法 |
-
2018
- 2018-10-22 CN CN201811230860.9A patent/CN109125411A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1197841A (zh) * | 1998-05-26 | 1998-11-04 | 倪颖 | 鹿宝酒及制备方法 |
CN104997079A (zh) * | 2015-08-06 | 2015-10-28 | 万雄集团股份有限公司 | 一种全鹿中药保健汤及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108815193A (zh) * | 2018-08-22 | 2018-11-16 | 宋子刚 | 一项仙鹿膏的中药配方及制备方法 |
CN113142565A (zh) * | 2021-04-19 | 2021-07-23 | 侯君才 | 一种鹿胶及其制备方法 |
CN114306387A (zh) * | 2022-01-19 | 2022-04-12 | 贵州广济堂健康药业有限公司 | 促进骨形成的药物及促进骨形成的方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080206375A1 (en) | Composition of Radix Codonopsis and Radix Astragali, a Method for Preparation Thereof and its Application | |
CN109125411A (zh) | 治疗骨质疏松的全鹿胶及其制备方法 | |
CN101524143A (zh) | 一种由蜂蜜和蜂王浆为主要原料制成的口服液 | |
CN108402460A (zh) | 一种增加骨密度的多功能食品组合物及其制备方法 | |
CN104127861B (zh) | 一种具有增加骨密度作用的药物组合物及其制备方法 | |
CN107260963A (zh) | 以铁皮石斛与莱菔子为主材制备治疗高血压药物的方法 | |
CN108434239A (zh) | 补气血抗疲劳口服液及其制备方法 | |
CN108514623A (zh) | 一种治疗肝肾亏虚型更年期综合征的药物及其制备方法 | |
CN108066712A (zh) | 一种补气养血中药组合物 | |
CN1718193A (zh) | 一种人参总次苷药物组合物及其制法和在制备治疗心肌缺血及失血性休克药物中的应用 | |
CN102784230B (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN107343925B (zh) | 一种治疗慢性心力衰竭的中药组合物及其制备方法 | |
CN102342974B (zh) | 一种治疗乳汁缺乏症的中药 | |
CN106806403B (zh) | 一种增加骨密度的中药复方组合物及其制备方法 | |
CN104740428B (zh) | 一种复方红衣补血药物制剂及其应用和检测方法 | |
CN103405542B (zh) | 一种治疗化疗后白细胞减少的中药 | |
CN108686034A (zh) | 一种拮抗肿瘤化疗后骨髓抑制的中药组合物及制备方法 | |
CN106728869A (zh) | 一种治疗尿毒症合并营养不良的药物及其制作方法 | |
CN109620911B (zh) | 一种具有改善化疗后中性粒细胞减少症的中药组合物及其用途 | |
CN106421408A (zh) | 一种用于治疗难治性心衰的药物组合物 | |
CN104606442B (zh) | 一种治疗肾精亏虚型绝经后骨质疏松症的中药组合物 | |
CN104547358A (zh) | 一种治疗脾肾阳虚型绝经后骨质疏松症的中药制剂 | |
CN104435693A (zh) | 一种治疗低血压的中药组合物 | |
CN104623268A (zh) | 一种治疗和预防妇女产后缺乳的中药组合物 | |
CN118078965A (zh) | 一种减少医学检查放射线损害的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190104 |
|
RJ01 | Rejection of invention patent application after publication |